Should you buy Haemonetics Corporation stock? (NYSE:HAE). Let's see how it does in our automated value investing analysis system.
(Haemonetics Corporation stock price per share)
||HAE Fair Price
(based on intrinsic value)
|HAE Safety Price (based on a variable margin of safety)||$15.98|
|PE Ratio versus Sector||453% higher than other Healthcare stocks|
|PE Ratio versus Industry||364% higher than other Medical Instruments & Supplies stocks|
|Free Cash Flow Jitter||80%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 1,700,588 shares shorted. With 50,809,525 shares available for purchase and an average trading volume over the past 10 trading days of 607,440, it would take at least 2.8 days for all of the short holders to cover their shorts.
We believe that Haemonetics Corporation may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Haemonetics Corporation looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.
Does Haemonetics Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles